PHAR News

Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026

Pharming Group to report first quarter 2026 financial results and provide business update on May 7

Pharming Group announces the 2026 Annual General Meeting of Shareholders

Pharming Group N.V. Investigated by the Portnoy Law Firm

Pharming Group to participate in April investor conferences

Pharming Group announces the filing of its 2025 Annual Report and Form 20-F

Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older

Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older

In Vivo Toxicology Market to Surpass USD 25.90 Billion by 2035; Rising Demand for Drug Safety Assessment and Expanding Biologics Pipeline Driving Market Growth – SNS Insider

Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow